Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06682013 · ClinicalTrials.gov registry record · NA

Virtual Agent Feasibility in Oncology Patients (NTT Data)

A NA study of Lung Cancer, sponsored by Duke University.

Recruiting
Registry status
NA
Development phase
36
Enrollment target
1
Study location

NCT06682013: Recruiting NA study of Lung Cancer, sponsored by Duke University.

NCT06682013 is a NA study of Lung Cancer that is actively recruiting participants, run by Duke University. The registered enrollment target is 36 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06682013, a NA study of Lung Cancer, is actively recruiting participants, sponsored by Duke University.

RECRUITING
Registry status
NA
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare the use of a virtual agent vs. a human agent when onboarding oncology patients over the telephone to Remote Patient Monitoring (RPM) devices. RPM devices are instruments that a patient can use to measure their own weight and vital signs. Both the virtual and human agents will be available by telephone to instruct the patient on how to use the RPM devices to measure weight, blood pressure, heart rate, temperature, and oxygen saturation. Patients will be randomized to either the virtual or human agent, have assessments of their medical and oncological history, overall well-being, body measurements, and vital signs, and will complete questionnaires about their experience.

Conditions Studied

Interventions

  • DEVICE Virtual agent
  • OTHER Human agent

Study Locations (1)

North Carolina

  • Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2026-04
Est. Completion 2026-08
Phase NA
Duke University

1,725 total trials

What NCT06682013 shows while recruiting

NCT06682013 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Virtual agent is the first listed.

NCT06682013 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT06682013 about?

NCT06682013 is a clinical study titled "Virtual Agent Feasibility in Oncology Patients (NTT Data)". The purpose of this study is to compare the use of a virtual agent vs. a human agent when onboarding oncology patients over the telephone to Remote Patient Monitoring (RPM) devices. RPM devices are instruments that a patient can use to measure their own weight and vital signs. Both the virtual and h...

What is the current status of trial NCT06682013?

This trial is currently recruiting. It is a NA study. The enrollment target is 36 participants. The study started on 2026-04. Estimated completion is 2026-08.

What conditions does trial NCT06682013 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT06682013?

The interventions under investigation include: Virtual agent (DEVICE), Human agent (OTHER).

Who is sponsoring clinical trial NCT06682013?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06682013 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06682013's enrollment target sits among peer trials

36 311th of 409 higher than 99 of 409 other Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT06682013, the US trial registry maintained by the National Library of Medicine. NCT06682013 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.